Skip to content

Arvinas ARVN Other income, net (Note 6)

Other income, net (Note 6) at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.92M+68.7%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$121K+403%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$12K+76.0%
Nuvation Bio logo
Nuvation BioNUVB
$562.75K+2,165%
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$0+100%
Erasca, Inc. logo
Erasca, Inc.ERAS
$22K+129%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's other income, net (note 6)?
Arvinas (ARVN) reported other income, net (note 6) of -$100K in Q1 2026.
What is the long-term trend for Arvinas's other income, net (note 6)?
Over 4 years (2021 to 2025), Arvinas's other income, net (note 6) has grown at a -36.1% compound annual growth rate (CAGR), from $2.4M to -$400K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.